These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis. Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361 [TBL] [Abstract][Full Text] [Related]
23. 5-HT3-receptor antagonists in the control of delayed-onset emesis. Gridelli C Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112 [TBL] [Abstract][Full Text] [Related]
24. 5-HT reuptake inhibitors in healthy human subjects. Netter P Clin Neuropharmacol; 1986; 9 Suppl 4():162-4. PubMed ID: 3105878 [No Abstract] [Full Text] [Related]
25. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Loewen PS; Marra CA; Zed PJ Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279 [TBL] [Abstract][Full Text] [Related]
26. Serotonin and psychiatric disorders. A key to new therapeutic approaches. Costall B; Naylor RJ Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395 [TBL] [Abstract][Full Text] [Related]
27. 5-HT3 antagonists in postoperative nausea and vomiting. Russell D; Kenny GN Br J Anaesth; 1992; 69(7 Suppl 1):63S-68S. PubMed ID: 1486016 [No Abstract] [Full Text] [Related]
28. Ritanserin (R 55667) an original thymosthenic. Hoppenbrowers ML; Gelders Y; Vanden Bussche G Boll Chim Farm; 1986 Dec; 125(12):136S-147S. PubMed ID: 3109453 [No Abstract] [Full Text] [Related]
29. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Gregory RE; Ettinger DS Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240 [TBL] [Abstract][Full Text] [Related]
30. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? Gan TJ CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177 [TBL] [Abstract][Full Text] [Related]
31. Current experience with 5-HT3 receptor antagonists in fibromyalgia. Späth M Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920 [TBL] [Abstract][Full Text] [Related]
33. Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist. Nakamura H; Yokoyama H; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y Biol Pharm Bull; 2013; 36(5):780-7. PubMed ID: 23459393 [TBL] [Abstract][Full Text] [Related]
34. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Wolf H Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830 [TBL] [Abstract][Full Text] [Related]
35. Concluding remarks and outlook for the use of 5-HT3 receptor antagonists in rheumatology. Pongratz D; Stratz T; Müller W Scand J Rheumatol Suppl; 2004; 119():79-80. PubMed ID: 15515422 [No Abstract] [Full Text] [Related]
36. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors. Costall B; Naylor RJ Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267 [TBL] [Abstract][Full Text] [Related]
37. The 5-HT3 receptor as a therapeutic target. Thompson AJ; Lummis SC Expert Opin Ther Targets; 2007 Apr; 11(4):527-40. PubMed ID: 17373882 [TBL] [Abstract][Full Text] [Related]
38. [5-HT3-receptor-antagonists in therapy of rheumatic diseases]. Müller W; Stratz T Z Rheumatol; 2003 Feb; 62(1):39-41. PubMed ID: 12624802 [No Abstract] [Full Text] [Related]
39. The serotonin re-uptake transporter as a target for antidepressant action. Langer SZ; Graham D; Arbilla S; Schoemaker H; Angel I Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():436A-437A. PubMed ID: 1498906 [No Abstract] [Full Text] [Related]